Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

SHR-A2009 plus EGFR tyrosine kinase inhibitor shows promising activity in EGFR-mutant lung cancer

Prof Yi-Long Wu - Guangdong Lung Cancer Institute, Guangzhou, China
SHR-A2009 plus EGFR tyrosine kinase inhibitor shows promising activity in EGFR-mutant lung cancer ( Prof Yi-Long Wu - Guangdong Lung Cancer Institute, Guangzhou, China )
14 Apr 2026

Subcutaneous amivantamab plus lazertinib shows durable responses in EGFR-mutant advanced lung cancer

Prof Nicolas Girard - Institut Curie, Paris, France
Subcutaneous amivantamab plus lazertinib shows durable responses in EGFR-mutant advanced lung cancer ( Prof Nicolas Girard - Institut Curie, Paris, France )
14 Apr 2026

Artificial intelligence PD-L1 scoring matches pathologists and improves reproducibility in lung cancer testing

Prof Fred Hirsch - Icahn School of Medicine at Mount Sinai, New York, USA
Artificial intelligence PD-L1 scoring matches pathologists and improves reproducibility in lung cancer testing ( Prof Fred Hirsch - Icahn School of Medicine at Mount Sinai, New York, USA )
14 Apr 2026

T-cell engagers in lung cancer: Strategies to prevent and manage toxicities

Dr Myung-Ju Ahn - Sungkyunkwan University School of Medicine, Seoul, South Korea
T-cell engagers in lung cancer: Strategies to prevent and manage toxicities ( Dr Myung-Ju Ahn - Sungkyunkwan University School of Medicine, Seoul, South Korea )
14 Apr 2026

Cracking the code: Bispecific immunotherapy in small cell lung cancer

Prof Helena Linardou - Metropolitan Hospital, Athens, Greece
Cracking the code: Bispecific immunotherapy in small cell lung cancer ( Prof Helena Linardou - Metropolitan Hospital, Athens, Greece )
13 Apr 2026

ATR inhibitor plus durvalumab does not improve survival over docetaxel in advanced NSCLC

Prof Benjamin Besse - Institut Gustave Roussy, Villejuif, France
ATR inhibitor plus durvalumab does not improve survival over docetaxel in advanced NSCLC ( Prof Benjamin Besse - Institut Gustave Roussy, Villejuif, France )
13 Apr 2026

Durvalumab after SBRT reduces tumour progression in early-stage NSCLC

Dr Andreas Hallqvist - Sahlgrenska University Hospital, Göteborg, Sweden
Durvalumab after SBRT reduces tumour progression in early-stage NSCLC ( Dr Andreas Hallqvist - Sahlgrenska University Hospital, Göteborg, Sweden )
13 Apr 2026

Gotistobart improves survival and response over docetaxel in previously treated squamous lung cancer

Dr Kai He - The Ohio State University Comprehensive Cancer Center, Columbus, USA
Gotistobart improves survival and response over docetaxel in previously treated squamous lung cancer ( Dr Kai He - The Ohio State University Comprehensive Cancer Center, Columbus, USA )
13 Apr 2026

Rituximab-based chemotherapy achieves strong outcomes without routine radiotherapy in stage I extranodal large B-cell lymphoma

Dr Konstantinos Christofyllakis - Saarland University, Saarbrücken, Germany
Rituximab-based chemotherapy achieves strong outcomes without routine radiotherapy in stage I extranodal large B-cell lymphoma ( Dr Konstantinos Christofyllakis - Saarland University, Saarbrücken, Germany )
30 Mar 2026

Encorafenib plus FOLFIRI improves response rates in BRAF-mutant metastatic colorectal cancer

Prof Scott Kopetz - MD Anderson Cancer Center, Housten, USA
Encorafenib plus FOLFIRI improves response rates in BRAF-mutant metastatic colorectal cancer ( Prof Scott Kopetz - MD Anderson Cancer Center, Housten, USA )
24 Mar 2026

Durvalumab plus chemotherapy improves outcomes and urine tumour DNA predicts response in muscle-invasive bladder cancer

Dr Michiel van der Heijden - Netherlands Cancer Institute, Amsterdam, Netherlands
Durvalumab plus chemotherapy improves outcomes and urine tumour DNA predicts response in muscle-invasive bladder cancer ( Dr Michiel van der Heijden - Netherlands Cancer Institute, Amsterdam, Netherlands )
23 Mar 2026

Zolbetuximab plus nivolumab and chemotherapy shows promising responses in CLDN18.2-positive metastatic gastric cancer

Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan
Zolbetuximab plus nivolumab and chemotherapy shows promising responses in CLDN18.2-positive metastatic gastric cancer ( Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan )
23 Mar 2026